论文部分内容阅读
目的分析改良消化道重建术联合替吉奥口服化疗治疗胃癌的临床疗效。方法将196例胃癌患者随机分为研究组与对照组各98例,研究组进行改良Roux-en-Y食管(胃)空肠吻合术,对照组进行Roux-en-Y食管(胃)空肠吻合术,比较2组患者重建时间、术中出血量、血清蛋白浓度、术后6个月Visick分级指数及并发症发生率。结果研究组患者重建消化道时间短于对照组,术中出血量少于对照组,血清总蛋白与血清白蛋白浓度均明显高于对照组,差异有统计学意义(P<0.05)。随访患者6个月,研究组患者中Visick指标Ⅰ级患者所占比例明显高于对照组Ⅰ级患者,Ⅲ级患者所占比例明显低于对照组,差异均有统计学意义(P<0.05),2组Ⅱ级与Ⅳ级患者所占比例差异均无统计学意义(P>0.05)。研究组腹泻、腹胀、反流性食管炎、倾倒综合征等并发症发生率为9.18%(9/98)明显低于对照组的34.69%(34/98),差异均有统计学意义(P<0.05)。结论改良Roux-en-Y食管(胃)空肠吻合术联合替吉奥口服化疗治疗胃癌操作简便,疗效显著,并发症少,在临床应用中具有重要的意义。
Objective To analyze the clinical effects of modified gastrointestinal reconstruction combined with TIGO oral chemotherapy for gastric cancer. Methods Ninety-six patients with gastric cancer were randomly divided into study group and control group, 98 cases in each group. The study group was performed Roux-en-Y esophagogastric jejunostomy. The control group received Roux-en-Y esophagogastric jejunostomy The reconstruction time, intraoperative blood loss, serum protein concentration, Visick grading index and complication rate were compared between the two groups. Results The study group was shorter than the control group in reconstructing the digestive tract. The blood loss in the study group was less than that in the control group. The serum total protein and serum albumin concentrations were significantly higher than those in the control group (P <0.05). Follow-up of patients for 6 months, the study group of patients with Visick index grade Ⅰ patients was significantly higher than the control group Ⅰ patients, Ⅲ grade patients was significantly lower than the proportion of the control group, the difference was statistically significant (P0.05) There was no significant difference in the proportion of grade Ⅱ and Ⅳ between the two groups (P> 0.05). The incidence of complications such as diarrhea, abdominal distension, reflux esophagitis and dumping syndrome was 9.18% (9/98) in the study group, which was significantly lower than 34.69% (34/98) in the control group (P <0.05). Conclusion The modified Roux-en-Y esophagogastric jejunostomy combined with TEGO oral chemotherapy for gastric cancer has the advantages of simple operation, significant curative effect and few complications, which is of great significance in clinical application.